Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, 24 Week, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSP-004184 (SPD602) in the Treatment of Chronic Iron Overload Requiring Chelation Therapy

NCT01604941 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01604941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01604941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, 24 Week, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSP-004184 (SPD602) in the Treatment of Chronic Iron Overload Requiring Chelation Therapy
Lead sponsor
Shire
Phase
Phase 2
Overall status
Terminated
Start date
September 14, 2012
Completion date
April 18, 2014
Enrollment
32 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

iron overload due to repeated red blood cell transfusions